PRINCETON, N.J. — August 21, 2025 — Leads & Copy — UroGen Pharma Ltd. (Nasdaq: URGN) will participate in investor conferences in September, the biotech company said today. The conferences are the Wells Fargo Healthcare Conference on Sept. 3 in Boston; the Cantor Fitzgerald Global Healthcare Conference on Sept. 4 in New York; and the H.C. Wainwright 27th Annual Global Healthcare Conference on Sept. 8, also in New York. Conference webcasts will be available through the Events section of the Company’s Investor Relations website, with replays available for 90 days.
UroGen develops and commercializes innovative solutions that treat urothelial and specialty cancers. Its RTGel reverse-thermal hydrogel is a sustained-release, hydrogel-based platform technology that may improve existing drugs’ therapeutic profiles. UroGen’s first product treats low-grade upper tract urothelial cancer, and its second product is the first FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. UroGen is based in Princeton, NJ, with operations in Israel.
INVESTORS: Vincent Perrone, Senior Director, Investor Relations, vincent.perrone@urogen.com, 609-460-3588 ext. 1093
MEDIA: Cindy Romano, Director, Corporate Communications, cindy.romano@urogen.com, 609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
